Search

Your search keyword '"Gheorghe, Liana"' showing total 16 results
Start Over Author "Gheorghe, Liana" Database Supplemental Index
16 results on '"Gheorghe, Liana"'

1. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

Author

Marshall, Alison D, Cunningham, Evan B, Nielsen, Stine, Aghemo, Alessio, Alho, Hannu, Backmund, Markus, Bruggmann, Philip, Dalgard, Olav, Seguin-Devaux, Carole, Flisiak, Robert, Foster, Graham R, Gheorghe, Liana, Goldberg, David, Goulis, Ioannis, Hickman, Matthew, Hoffmann, Patrick, Jancorienė, Ligita, Jarcuska, Peter, Kåberg, Martin, Kostrikis, Leondios G, Makara, Mihály, Maimets, Matti, Marinho, Rui Tato, Matičič, Mojca, Norris, Suzanne, Ólafsson, Sigurður, Øvrehus, Anne, Pawlotsky, Jean-Michel, Pocock, James, Robaeys, Geert, Roncero, Carlos, Simonova, Marieta, Sperl, Jan, Tait, Michele, Tolmane, Ieva, Tomaselli, Stefan, van der Valk, Marc, Vince, Adriana, Dore, Gregory J, Lazarus, Jeffrey V, and Grebely, Jason

Abstract

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.

Published
2018
Full Text
View/download PDF

2. Diagnostic Delay in Romanian Patients with Inflammatory Bowel Disease: Risk Factors and Impact on the Disease Course and Need for Surgery.

Author

Zaharie, Roxana, Tantau, Alina, Zaharie, Florin, Tantau, Marcel, Gheorghe, Liana, Gheorghe, Cristian, Gologan, Serban, Cijevschi, Cristina, Trifan, Anca, Dobru, Daniela, Goldis, Adrian, Constantinescu, Gabriel, Iacob, Razvan, and Diculescu, Mircea

Abstract

Background: The epidemiology of inflammatory bowel disease [IBD] in Eastern Europe is poorly understood, particularly with regard to diagnostic delay. Here we investigated the factors leading to delayed diagnosis and the effect of the delay on several disease progression and outcome measures. Methods: A total of 1196 IBD cases [682 ulcerative colitis [UC], 478 Crohn's disease [CD], 36 indeterminate colitis] from the Romanian national registry IBDPROSPECT were reviewed. Standard clinical and demographic factors were evaluated as predictors of a long diagnostic delay in both CD and UC. Diagnostic delay was subsequently evaluated as a potential risk factor for bowel stenoses, bowel fistulas, perianal fistulas, perianal surgery, and intestinal surgery in CD patients. Results: The median diagnostic delay was significantly longer in CD [5 months] than in UC [1 month] patients [p < 0.001]. Compared with 5 months for UC patients, 75% of CD patients were diagnosed within 18 months of symptom onset. In CD patients, extra-ileal location was a protective factor (odds ratio [OR], 0.5; p = 0.03), whereas being an active smoker [OR, 2.09; p = 0.01] and symptom onset during summer [OR, 3.35; p < 0.001] were independent risk factors for a long diagnostic delay [> 18 months]. In UC patients, an age > 40 years was a protective factor [OR, 0.68; p = 0.04] for a long delay. Regarding outcomes, a long diagnostic delay in CD patients positively correlated with bowel stenoses [OR, 3.38; p < 0.01] and any IBD-related surgery [OR, 1.95; p = 0.03] and had a positive trend for intestinal fistulas [OR, 2.64; p = 0.08] and perianal fistulas [OR, 2.9; p = 0.07]. Disease duration since diagnosis positively correlated with bowel stenoses [OR, 1.04; p = 0.04], any IBD-related surgery [OR, 1.04; p = 0.02], and intestinal surgery [OR, 1.07; p < 0.01]. Conclusions: A long diagnostic delay in IBD correlates with an increased frequency of bowel stenoses and need for IBD-related surgery. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

3. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Author

Razavi, Homie, Robbins, Sarah, Zeuzem, Stefan, Negro, Francesco, Buti, Maria, Duberg, Ann-Sofi, Roudot-Thoraval, Françoise, Craxi, Antonio, Manns, Michael, Marinho, Rui T, Hunyady, Bela, Colombo, Massimo, Aleman, Soo, Antonov, Krasimir, Arkkila, Perttu, Athanasakis, Kostas, Blach, Sarah, Blachier, Martin, Blasco, Antonio J, Calinas, Filipe, Calleja, Jose L, Christensen, Peer B, Cramp, Matthew E, Croes, Esther, de Knegt, Robert J, de Ledinghen, Victor, Delile, Jean-Michel, Estes, Chris, Falconer, Karolin, Färkkilä, Martti, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Gheorghe, Liana, Goldis, Adrian, Gountas, Ilias, Gregorčič, Sergeja, Gschwantler, Michael, Gunter, Jessie, Halota, Waldemar, Harcouet, Laura, Hézode, Christophe, Hoffmann, Patrick, Horvath, Gabor, Hrstic, Irena, Jarčuška, Peter, Jelev, Deian, Jeruma, Agita, Kåberg, Martin, Kieran, Jennifer, Kondili, Loreta A, Kotzev, Iskren, Krarup, Henrik, Kristian, Pavol, Lagging, Martin, Laleman, Wim, Lázaro, Pablo, Liakina, Valentina, Lukšić, Boris, Maimets, Matti, Makara, Mihály, Mateva, Lyudmila, Maticic, Mojca, Mennini, Francesco S, Mitova, Rumiana, Moreno, Christophe, Mossong, Joel, Murphy, Kimberly, Nde, Helen, Nemecek, Vratislav, Nonkovic, Dijana, Norris, Suzanne, Oltman, Marian, Øvrehus, Anne L H, Papatheodoridis, George, Pasini, Ken, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Reesink, Henk W, Reic, Tatjana, Rozentale, Baiba, Ryder, Stephen D, Salupere, Riina, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Simojoki, Kaarlo, Simonova, Marietta, Smit, Peter J, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Struck, Daniel, Sypsa, Vana, Thornton, Lelia, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van de Vijver, David, van der Meer, Adriaan J, van Santen, Daniela, Van Vlierberghe, Hans, Vandijck, Dominique, Vella, Stefano, Videčnik-Zorman, Jerneja, Vogel, Wolfgang, Weis, Nina, and Hatzakis, Angelos

Abstract

Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination.

Published
2017
Full Text
View/download PDF

4. Predictors of Graft and Patient Survival in Hepatitis C Virus (HCV) Recipients Model to Predict HCV Cirrhosis After Liver Transplantation

Author

Iacob, Speranta, Cicinnati, Vito R., Hilgard, Philip, Iacob, Razvan A., Gheorghe, Liana S., Popescu, Irinel, Frilling, Andrea, Malago, Massimo, Gerken, Guido, Broelsch, Christoph E., and Beckebaum, Susanne

Abstract

Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is almost universal, but the natural history of recurrent HCV in the allograft is highly variable. Our study had two aims: 1) to assess the impact of different pre- and postLT factors on graft and patient survival in HCV transplant recipients and 2) to create a model which may predict the patients at risk for HCV-related graft cirrhosis at 5 years postLT.

Published
2007
Full Text
View/download PDF

5. Homozygous familial hypercholesterolemia specific indication for domino liver transplantation

Author

Popescu, Irinel, Simionescu, Maya, Tulbure, Dan, Sima, Anca, Catana, Cosmin, Niculescu, Loredan, Hancu, Nicolae, Gheorghe, Liana, Mihaila, Mariana, Ciurea, Silviu, and Vidu, Viorica

Abstract

Domino liver transplantation is one possibility to overcome the discrepancy between the small number of liver donors and the long waiting lists. Homozygous familial hypercholesterolemia (FHC) is a genetic disorder of lipoprotein metabolism defined by the absence or small number of functional low-density lipoprotein receptors (LDL-Rs) and the ensuing high levels of serum cholesterol. We report a case of a patient with FHC whose liver was used for domino transplantation in a patient with cirrhosis and hepatocellular carcinoma.

Published
2003
Full Text
View/download PDF

6. Tu1541 - Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir Plus/Minus Ribavirin for Treatment of HCV Genotype 1B Compensated Cirrhosis in Patients Aged 70 Years or Older.

Author

Trifan, Anca, Prelipcean, Cristina Cijevschi, Gheorghe, Liana, Curescu, Manuela, Brisc, Ciprian, Bataga, Simona, Miftode, Egidia, Arama, Victoria, Rogoveanu, Ion, Suceveanu, Andra Iulia, Singeap, Ana Maria, Chiriac, Stefan A., Cuciureanu, Tudor, Sporea, Ioan, Goldis, Adrian, Popescu, Alina, Iacob, Speranta, Sfarti, Catalin, Cojocariu, Camelia, and Stefanescu, Gabriela

Published
2017
Full Text
View/download PDF

9. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

Author

Trifan, Anca, Stanciu, Carol, Gheorghe, Liana, Iacob, Speranta, Curescu, Manuela, Cijevschi Prelipcean, Cristina, Stefanescu, Gabriela, Girleanu, Irina, Chiriac, Stefan, Mihai, Catalina, Brisc, Ciprian, Goldis, Adrian, Sporea, Ioan, Miftode, Egidia, Bataga, Simona, Rogoveanu, Ion, Preda, Carmen, Caruntu, Florin Alexandru, Singeap, Ana-Maria, and Enomoto., Hirayuki

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results